MediWound (NASDAQ: MDWD) and Mirna Therapeutics (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Insider and Institutional Ownership

19.5% of MediWound shares are held by institutional investors. 18.6% of Mirna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

MediWound has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Mirna Therapeutics has a beta of 4, meaning that its stock price is 300% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for MediWound and Mirna Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediWound 0 0 5 0 3.00
Mirna Therapeutics 0 2 1 0 2.33

MediWound presently has a consensus target price of $10.00, suggesting a potential upside of 100.00%. Mirna Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 30.09%. Given MediWound’s stronger consensus rating and higher probable upside, research analysts plainly believe MediWound is more favorable than Mirna Therapeutics.

Earnings and Valuation

This table compares MediWound and Mirna Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
MediWound $2.17 million 60.72 -$16.18 million ($0.75) -6.67
Mirna Therapeutics N/A N/A N/A ($9.59) -1.56

Mirna Therapeutics has higher revenue, but lower earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Mirna Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares MediWound and Mirna Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MediWound -752.78% -326.32% -48.65%
Mirna Therapeutics N/A -44.70% -42.29%


MediWound beats Mirna Therapeutics on 6 of the 11 factors compared between the two stocks.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

About Mirna Therapeutics

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.